Article
Prognostic Value of Exon 19 Versus 21 EGFR Mutations Varies According to Disease Stage in Surgically Resected Non-small Cell Lung Cancer Adenocarcinoma.
Annals of surgical oncology - 1 Apr 2018
Renaud Stéphane, Seitlinger Joseph, Guerrera Francesco, Reeb Jérémie, Beau-Faller Michèle, Voegeli Anne-Claire, Siat Joelle, Clément-Duchêne Christelle, Tiotiu Angelica, Santelmo Nicola, Costardi Lorena, Ruffini Enrico, Falcoz Pierre-Emmanuel, Vignaud Jean-Michel, Massard Gilbert
Abstract excerpt
BACKGROUND: The prognostic value of exon 19 and 21 EGFR mutations in stage IV non-small cell lung cancer (NSCLC) is well established. OBJECTIVE: We aimed to evaluate the prognostic value of the mutations in surgically resected NSCLC. METHODS: We retrospectively reviewed data from 1798 surgically resected NSCLC adenocarcinomas between 2007 and 2017 in three departments of thoracic surgery (Nancy/Strasbourg,...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
